



# HHS Public Access

Author manuscript

*J Clin Epidemiol.* Author manuscript; available in PMC 2024 February 01.

Published in final edited form as:

*J Clin Epidemiol.* 2023 February ; 154: 136–145. doi:10.1016/j.jclinepi.2022.12.013.

## No Short-Term Mortality from Benzodiazepine Use Post-Acute Ischemic Stroke After Accounting for Bias

Lidia M.V.R. Moura, MD, PhD, MPH<sup>a,b</sup>, Zhiyu Yan, MS<sup>a</sup>, Maria A. Donahue, MD<sup>a</sup>, Louisa H. Smith, PhD<sup>i</sup>, Lee H. Schwamm, MD<sup>a,b</sup>, John Hsu, MD, MBA, MSCE<sup>c,d,e</sup>, Joseph P. Newhouse, PhD<sup>c,f,g,h</sup>, Sebastien Haneuse, PhD<sup>l</sup>, Deborah Blacker, MD, ScD<sup>i,j,k</sup>, Sonia Hernandez-Diaz, MD, DPH<sup>i</sup>

<sup>a</sup>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.

<sup>b</sup>Department of Neurology, Harvard Medical School, Boston, Massachusetts.

<sup>c</sup>Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

<sup>d</sup>Mongan Institute, Massachusetts General Hospital, Boston, Massachusetts.

<sup>e</sup>Department of Medicine, Harvard Medical School, Boston, Massachusetts.

<sup>f</sup>National Bureau of Economic Research, Cambridge, Massachusetts.

<sup>g</sup>Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

<sup>h</sup>Harvard Kennedy School, Cambridge, Massachusetts.

<sup>i</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

<sup>j</sup>Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.

<sup>k</sup>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

<sup>l</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.

### Abstract

**Corresponding Author:** Lidia M.V.R. Moura, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, lidia.moura@mgh.harvard.edu.

Conflicts of Interest:

The authors declare no conflict of interest.

CRediT Author Statement:

Dr. Lidia Moura: conceptualization, methodology, formal analysis, data curation, writing – original draft, writing – review & editing, funding acquisition, supervision. Dr. Maria A Donahue: writing – original draft, writing – review & editing, visualization, project administration. Zhiyu Yan: software, validation, formal analysis, data curation, visualization. Louisa Smith: validation, formal analysis, writing – review & editing. Dr. Hsu: writing – review & editing. Dr. Schwamm: writing – review & editing. Dr. Newhouse: writing – review & editing. Drs. Haneuse: conceptualization, methodology, formal analysis, writing – review & editing. Dr. Blacker: conceptualization, methodology, writing – review & editing. Dr. Hernandez-Diaz: conceptualization, methodology, formal analysis, writing – review & editing, and supervision.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


**Objective:** Older adults receive benzodiazepines for agitation, anxiety, and insomnia after acute ischemic stroke (AIS). No trials have been conducted to determine if benzodiazepine use affects post-stroke mortality in the elderly.

**Study Design and Setting:** We examined the association between initiating benzodiazepines within one week after AIS and 30-day mortality. We included patients  $\geq 65$  years, admitted for new non-severe AIS (NIH-Stroke-Severity[NIHSS]  $\leq 20$ ), 2014–2020, with no recorded benzodiazepine use in the previous three months and no contraindication for use. We linked a stroke registry to electronic health records, used inverse-probability weighting to address confounding, and estimated the risk difference (RD). A process of cloning, weighting, and censoring was used to avoid immortal time bias.

**Results:** Among 2,584 patients, 389 received benzodiazepines. The crude 30-day mortality risk from treatment initiation was 212/1,000 among patients who received benzodiazepines, while the 30-day mortality was 34/1,000 among those who did not. When follow-up was aligned on day of AIS admission and immortal time was assigned to the two groups, the estimated risks were 27/1,000 and 22/1,000, respectively. Upon further adjustment for confounders, the RD was 5 (–12 to 19) deaths/1,000 patients.

**Conclusion:** The observed higher 30-day mortality associated with benzodiazepine initiation within seven days was largely due to bias.

## Graphical Abstract



## Keywords

Neurology; Stroke; Mortality; Benzodiazepines; Acute Ischemic Stroke; Polytherapy

## 1. INTRODUCTION

Acute Ischemic Stroke (AIS) is a common cause of both short-term mortality and long-term disability in older adults.<sup>1</sup> For those ≥ 65 years, stroke is the second leading cause of hospitalization and carries a 10-fold higher mortality risk compared with younger patients.<sup>2</sup> Benzodiazepines are often indicated for complications and procedures related to stroke care. For instance, post-stroke insomnia, periprocedural anxiety, and delirium may complicate stroke hospitalizations and are increasingly treated with benzodiazepines.<sup>3–6</sup> Medical organizations suggest avoiding benzodiazepines in those ≥ 65 years<sup>3–8</sup> because they may cause adverse effects including excessive somnolence and falls.<sup>9,10</sup> Older adults on polytherapy are more sensitive to drug toxicity, as are those with acute brain insults such as an AIS. Since older adults are typically excluded from randomized clinical trials,<sup>11,12</sup> the effect of benzodiazepines remains unclear in this population.<sup>13,14</sup>

We evaluated the association of benzodiazepine initiation during the acute phase of AIS recovery on 30-day mortality among patients ≥ 65 years. To reduce confounding by indication in the context of a non-randomized study we restricted to patients with non-severe AIS and adjusted for clinical and sociodemographic characteristics.<sup>15–19</sup> The study design aligned start of follow-up for treatment groups while accounting for the immortal time between AIS admission and benzodiazepine administration.

## 2. METHODS

### 2.1 Study Design

We used a target trial approach to emulate a hypothetical pragmatic randomized clinical trial.<sup>15,16,18,20–23</sup> Specifying the ideal trial that would answer the research question forces a rigorous conceptualization of the study design components, as well as the assumptions necessary to answer the question using observational data.<sup>18</sup> One potential target trial to answer the question of interest would randomly assign eligible patients at the time of AIS admission to one of two treatment strategies: (a) initiate benzodiazepines at the label-recommended dose regimen within seven days of admission, or b) no benzodiazepines within the same seven-day post-AIS period. Next, we describe the observational study we conducted to emulate this target trial (Table 1).

### 2.2 Setting & Data Sources

We used electronic health records stored in the Mass General Brigham (MGB) system to identify the eligible sample: patients admitted to the Massachusetts General Hospital.<sup>24</sup> These records had data on inpatient diagnoses, procedures, outpatient, and inpatient drug administration. We linked these data to the American Heart Association's Get With The Guidelines (GWTG) Stroke Registry.<sup>25</sup> The GWTG collected patient sociodemographic, health history, and clinical data detailing the stroke admission including stroke severity assessment defined by the validated Stroke Severity scale, NIHSS.<sup>26,27</sup> Each patient discharged from MGB with a stroke diagnosis had their data checked for quality and submitted to the GWTG Registry.<sup>25</sup>

### 2.3 Study Population

From January 1, 2014, to December 31, 2020, we identified 3,343 patients  $\geq 65$  years who were admitted for AIS,<sup>25</sup> and had no recorded diagnosis of prior AIS in the last twelve months. We excluded 44 patients without the minimum information in the electronic health records to determine eligibility (NIHSS recorded at admission). We also excluded patients with a diagnosis of myasthenia gravis, a contraindication to benzodiazepines, in the previous twelve months, or who received one or more recorded prescriptions of benzodiazepines in the three months prior to admission. The final eligible sample was 2,584 (Figure 1). Because those with a severe AIS would be most likely intubated and medicated with anesthetics, they would not be suitable for examining the effect of benzodiazepines on mortality due to respiratory depression or falls. Also, the confounding by indications (e.g., procedures, palliative care) would be largest in observational data. Therefore, we restricted the sample to those with an NIHSS  $\leq 20$ , meaning mild, moderate, and moderate-to-severe AIS.<sup>24</sup> We estimated that our study would have a power greater than 80% for any sample size over 250 individuals for any risk difference greater than or equal to 10, given any pooled standard deviation smaller than or equal to 20 and minimum acceptable probability of preventing type I error of 95%.

### 2.4 Treatment Strategies

We defined the following treatment strategies: a) initiate benzodiazepines within seven days of admission, or b) do not treat with benzodiazepines during these seven days. In the target trial emulation, we obtained information on benzodiazepine use from inpatient and outpatient pharmacy claims data. Unlike in a randomized trial, we could not know which treatment strategy the patient had been assigned to until the day of the prescription (for those exposed) or seven days post-AIS (for those unexposed). Therefore, for patients who died within seven days without initiation, we could not know if they would have received treatment had they not died. Thus, for the seven days post-AIS, follow-up days until treatment initiation or death count towards both treatment strategies. To carry out such counting, we duplicated the dataset, creating “clones” of each patient so that each clone would contribute to both treatment strategies until their strategy is known. The follow-up of a clone is censored when its treatment strategy is violated, i.e., clones assigned to no-initiation were censored if they initiated treatment within those seven days, and clones assigned to initiation were censored if they did not initiate by day seven. At most, one clone remains in the dataset after the first seven days of follow-up. Lastly, the generated pseudo-population of clones for each treatment strategy is weighted by inverse probability weights to correct for the fact that the same patient does not adhere to both treatment strategies.<sup>28–32</sup> To mimic randomization, these weights also account for the non-random treatment initiation.<sup>18,33,34</sup> This “cloning-censoring-weighting” approach has been used in previous studies<sup>28</sup> and avoids a common methodological problem in observational data in the presence of staggered treatment initiation.

### 2.5 Emulated Randomization & Covariates

In the target trial, balanced baseline characteristics would be attained through randomization. In the emulation we ascertained information on clinical and

sociodemographic characteristics, assessed differences in their distribution between treated and non-treated groups, and standardized for relevant confounders in the analysis.

As our measure of stroke severity at baseline, we chose the NIHSS,<sup>26,27</sup> a summary measure that has been strongly associated with benzodiazepine initiation and mortality. NIHSS was reliably assessed, measured, and documented upon hospital admission (study time zero), making it an ideal baseline measure for use in the weights for treatment initiation. We also considered baseline comorbidities and prescription drug utilization prior to the AIS using data from 90 days prior to admission and obtained several sociodemographic measures from the MGB database such as age, sex, race, and ethnicity.<sup>35</sup>

As time varying characteristics, during the 7-day window, we used a comprehensive list of clinical and healthcare utilization variables, including inpatient and outpatient visits and pertinent procedures related to AIS management and cumulative in-hospital prescription count (excluding benzodiazepines). Further, we used Comfort-Measures-Only (CMO) status to adjust for adverse outcomes and end-of-life decisions made during the hospitalization but prior to the administration of benzodiazepines that may have influenced the decision to prescribe them. The Supplementary Text and Table B.1 detail each measure of interest, including ICD codes used to identify delirium for the analysis.

## 2.6 Follow-up & Outcome – 30-day Mortality

Patients were followed from AIS admission for 30 days or until death (Figure A.1). We examined a 30-day mortality because it has been previously endorsed by medical practice societies as a hospital performance measure and has been increasingly used in the context of value-based healthcare assessment and public reporting.<sup>36–38</sup> We extracted death date from the Electronic Health Records (EHR) Demographics data file (Death Master File). MGB updated death data monthly from the Social Security Administration. Deaths were captured even if the patient was transferred to a nursing home or another non-MGB facility (i.e., no losses to follow-up).

## 2.7 Statistical Analysis

We first described the characteristics of the eligible sample.<sup>39,40</sup> We obtained naïve crude 30-day mortality estimates for benzodiazepine initiators from treatment during the first-week post-AIS and for non-initiators from AIS admission.<sup>41,42</sup>

To evaluate the effect of benzodiazepine initiation in the first seven days post-AIS on 30-day mortality we estimated mortality probabilities using model-based predictions of the conditional survival for each day under each treatment strategy. To do so, we first estimated inverse-probability weights by modeling treatment initiation in the original dataset, duplicated the dataset to create “clones”, censored the clones as previously described, and assigned them appropriate weights to rebalance the two groups (cloning-censoring-weighting).<sup>20</sup> The model for treatment initiation during the grace period was a pooled logistic regression over person-days and included age, race, and NIHSS, all measured at admission, and post-admission measures of daily prescription count and CMO status, as well as a time-varying intercept (see Table B.2 for model parameters for estimating

benzodiazepine initiation weights). We provide model specifications and additional details on statistical analysis in the Supplementary Text.

In the weighted dataset, we fit a time-varying pooled logistic regression model for death as a function of treatment strategy (i.e., an indicator of which strategy a given clone belonged to) and interaction terms between treatment strategy and time, measured in days from admission until the end of the follow-up to allow for time-varying effects. From this model, we predicted mortality probabilities for each day under each treatment strategy.<sup>43–45</sup> We estimated absolute differences in mean 30-day mortality. To illustrate the magnitude of confounding bias beyond the selection or immortal person-time biases avoided by the clone-censor-weight approach we repeated the analysis without confounders in the model for treatment initiation during the grace period (the model corrected only for the duplications in the pseudo-population of clones).

We later examined the adequacy of this assumption using a visual inspection of the standardized mortality curves. We obtained 95% confidence intervals for all measures using the bootstrap with 500 replications.

## 2.8 Missing Data & Pre-Planned Stratified Analysis

We examined patterns of missingness for all pertinent variables to confirm that the analysis had negligible information. Benzodiazepines may be more harmful to older patients, as well as for patients with moderate-to-severe stroke relative to less severe stroke, as both are more likely to suffer adverse events like falls or intubation after the sedating effects of benzodiazepines. Therefore, we repeated the above analyses stratified by categories of age and NIHSS.

## 3. RESULTS

### 3.1 Characteristics of the Study Population

Among AIS patients < 65 years, 2,584 were eligible for our emulated trial. Of those, 389 initiated a benzodiazepine within seven days post-stroke. Table 2 describes patient characteristics among benzodiazepine initiators and versus non-initiators (Table B.3 includes additional time-varying measures). Tables B.4–B.6 show the population characteristics stratified by age and NIHSS category. The most frequently prescribed benzodiazepine was lorazepam (89.16%; Table B.7). 14.81% of the benzodiazepine initiators received a second anticonvulsant on or after the day of benzodiazepine initiation (Table B.8.).

### 3.2 Outcome – Mortality

Figure 2 provides crude and standardized curves for all 2,584 eligible patients, by benzodiazepine initiation strategy during the first 30 days post-stroke admission. The crude 30-day mortality counted from treatment initiation was 212 deaths/1000 patients who initiated benzodiazepines within seven days. The crude 30-day mortality counted from AIS admission was 34/1000 among non-initiators. When further correcting for confounding, standardized 30-day mortality was 27 (95% CI, 12–39) deaths/1000 patients who initiated

benzodiazepines and 22 (95% CI, 11–33) per 1000 non-initiators, yielding a risk difference of 5 (95% CI, –12–19) deaths/1000 patients.

Inspection of the curves suggests greater mortality rates for the initiate-benzodiazepine strategy compared to no-initiation, especially early after the admission, although confidence intervals overlap.

Among AIS patients 65–74 years and ≥74 years, there were –4 (95% CI –31–11) and 13 (95% CI –23–77) excess deaths per 1000 patients, respectively. Among patients with moderate-to-severe stroke (NIHSS 16–20), 30-day mortality was 115 (95%CI, 60–297) per 1000 patients who initiated benzodiazepines and 135 (95%CI, 37–236) deaths per 1000 patients in the no initiation of benzodiazepine strategy, a difference of –21 (95%CI, –122 to 200) deaths per 1000. Figures B.2–B.3 and Tables B.9–B.10, present the additional standardized survival curves and results, stratified by age groups, and stroke severity, respectively. When CMO determination happened after admission, we accounted for CMO status as a time-varying characteristic. Table B.11 displays this study’s compliance with reporting recommendations. The Supplementary Text provides the Statistical Code used to conduct the main analysis.

#### 4. DISCUSSION

In this study, using the information on predictors of benzodiazepine use and mortality among AIS patients ≥65 years, the estimated difference in 30-day mortality was reduced from 178 excess cases per 1000 initiators in the crude naïve analysis to 27 per 1000 cases after avoiding selection and immortal time biases, to 5 per 1000 cases after additionally addressing bias from measured confounders.

Benzodiazepine use has been associated with an earlier need for intubation due to oversedation, consequently increasing the risk of hospital-acquired pneumonia and further increasing patient morbidity.<sup>46</sup> However, providers commonly treat anxiety, insomnia, and agitation with benzodiazepines, even among patients at advanced ages, despite growing concerns that these medications could precipitate death and should be avoided in this population.<sup>4,47</sup> Existing guidelines are unclear with respect to which type of patients would be harmed more by benzodiazepines and do not highlight which vulnerable subgroups merit special attention.<sup>48,49</sup> Since a clinical trial is implausible, we used real-world evidence to emulate a hypothetical pragmatic trial. Quantifying the effect of benzodiazepines on mortality using observational data is not straightforward because of confounding by indication, as demonstrated by our results in which benzodiazepine initiators had a more severe stroke, were more often CMO, and had more comorbidities and concomitant medication.<sup>28</sup>

Benzodiazepine use could affect mortality by affecting complications (increasing or preventing), but also affecting the length of hospitalization (increasing observation), or discharge destination (e.g., more likely to a clinical facility). While there was no marginal 30-days mortality risk difference in this study, there could still be potential short-term effects caused by benzodiazepine initiation, such as increased delirium risk, aspiration pneumonia,

and other complications. In resource-limited settings, patients may suffer from prescription discontinuation inertia, and medication management strategies could be directed towards those at higher risk for drug utilization. This manuscript describes the populations most at risk of adverse effects caused by benzodiazepine use and challenges further studies that could inform current guidelines to ultimately decrease benzodiazepine-related mortality.

#### 4.1 Strengths

Our approach has several important strengths when compared to previous studies in the presence of staggered treatment initiation.<sup>29–32</sup> First, rather than using post-baseline information to define exposure strategies at AIS admission,<sup>19</sup> allowed patients to contribute person-time to both treatment strategies during the grace period before they start benzodiazepines or die.<sup>20</sup> This avoids immortal time bias by not counting the time between the start of follow-up and benzodiazepine initiation only in the exposed group. Second, rather than starting follow-up on day 7, it aligned the start of follow-up at admission for every patient in the study, thus avoiding a biased selection of survivors in the benzodiazepine group. Third, rather than moving the start of follow-up for the benzodiazepine group to the time of treatment initiation, it aligned time-zero for exposed and reference groups, thus comparing the same periods post-AIS, when there is substantially larger mortality in the first days.

To address confounding we linked multiple data sources, incorporating granular measurements of both baseline variables and time-dependent covariates up to treatment strategy assignment, and statistical methods of addressing time-dependent confounding.<sup>15</sup> Lastly, there were no losses to follow-up since we had information on mortality, even after the patient stopped using the healthcare system.

#### 4.2 Limitations

**Residual confounding.**—Our crude versus standardized analysis on the additive scale showed substantial confounding raising concern about potential residual confounder. Intubation is an indication of benzodiazepines that can be associated with mortality because it is more commonly done for severe patients. We tried to account for severity by restricting to those less severe cases (e.g., NIHSS  $\geq 20$ ) and by adjusting for stroke severity markers directly (e.g., NIHSS, prescription counts, etc.). Specific measures of frailty (e.g., unintentional weight loss, exhaustion, low energy expenditure, low grip strength, and/or slowed walking speed) would have been helpful to have for this population. However, variables regarding adverse outcomes or complications such as aspiration pneumonia, DVT, tracheostomy, or percutaneous endoscopic gastrostomy, would have provided additional confounding. The assumption is that after adjustment for several determinants of mortality the residual confounding by unrecorded measures would be minimal.

Among 389 benzodiazepine initiators, 15% received a non-benzodiazepine anticonvulsant on or after the day of benzodiazepine initiation (Table B.8), consistent with the common indication of peri-procedural anxiety or agitation, where use is frequently “as needed”, where the medication may or may not be used and where the frequency of administration is more difficult to determine based on documentation in the EHR. Therefore, most measures



associated with receipt of benzodiazepine and mortality were highly correlated with baseline stroke severity (e.g., CMO), which suggests that adjustment for NIHSS scores is likely adjusting for other unmeasured confounders.

**Generalizability.**—Our inclusion and exclusion criteria might have favored the selection of patients with greater previous use of the healthcare system. In the tradeoff between generalizability and internal validity, we favored the latter by obtaining rich baseline data from those using healthcare to control for confounding. We examined benzodiazepines not typically used for anesthesia (i.e., we did not include midazolam infusions in this study); the most frequent benzodiazepines given in our study population was lorazepam (89%). Future studies could examine the mortality effect by drug type, dose, and duration of use in different care settings (inpatient vs outpatient).

**Power.**—Overall mortality risk was low in our sample, especially in the mild or moderate stroke severity stratum, which generated large confidence intervals. Our mortality results likely represent the lower bounds of benzodiazepine exposure risk in comparison to other settings because our study took place in a certified Advanced Stroke Center that can treat patients with AIS with high quality, despite receiving the most complex cases.<sup>3</sup> The stratified analyses for stroke severity and age subgroups were based on small numbers, and thus confidence intervals were wide. Further efforts are warranted to determine the benefit or harm to older patients from different treatment strategies during the acute and post-acute stroke recovery periods.

## 5. CONCLUSIONS

Among patients  $\geq 65$  years, the higher 30-day mortality associated with initiating benzodiazepines within seven days post-AIS compared to no benzodiazepines was largely due to bias. This study highlights the importance of appropriate methods to address selection and confounding biases.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGEMENTS

Sponsor's Role:

This work was done as part of the fulfillment of Dr. Moura's doctoral degree in Population Health Sciences (Epidemiology) at the Harvard T.H. Chan School of Public Health.

Financial Disclosures:

L.M.V.R.M.: Support from the Centers for Diseases Control and Prevention (U48DP006377), the National Institutes of Health (NIH-NIA 5K08AG053380-02, NIH-NIA 5R01AG062282-02, NIH-NIA 2P01AG032952-11, NIH-NIA 3R01AG062282-03S1), and the Epilepsy Foundation of America and reports no conflict of interest.

Z.Y., M.A.D. and L.H.S.: have no conflict of interest to disclose.

J.P.N. receives funding from NIH (2P01- AG032952, T32-AG51108) and reports being a director of Aetna until May 2018 and holding equity in Aetna until November 2018.

L.H.S.: Scientific consultant regarding trial design and conduct on late window thrombolysis and member of steering committee for Genentech (TIMELESS NCT03785678); user interface design and usability to LifeImage; stroke systems of care to the Massachusetts Dept of Public Health; member of a Data Safety Monitoring Board for Penumbra (MIND NCT03342664); Diffusion Pharma (PHAST-TSC NCT03763929); principal investigator, multicenter trial of stroke prevention for Medtronic (Stroke AF NCT02700945); principal investigator, StrokeNet Network NINDS (New England Regional Coordinating Center U24NS107243).

J.H.: Support from the NIH (1R01AG062282-012, P01AG032952).

J.P.N.: receives funding from NIH (2P01- AG032952, T32-AG51108) and reports being a director of Aetna until May 2018 and holding equity in Aetna until November 2018.

S.H.: Support from the NIH (R01HD098421, R01NS104143, P50CA244433, 1R01DK128150-01, R01DK107972) and Gates Foundation (INV-003612) reports no conflict of interest.

D.B.: Support from the NIH (5P30 AG062421-03, 2P01AG036694-11, 5U01AG032984-12, 1U24NS100591-04, 1R01AG058063-04, R01AG063975-03, 5R01AG062282-04, 3R01AG062282-03S1, 5R01AG066793-02, 1U19AG062682-03, 2P01AG032952-11, 2T32MH017119-34 Billing Agreement 010289.0001, 3P01AG032952-12S3, 1U01AG068221-01, 1U01AG076478-01, 5R01AG048351-05) and 747021.Blacker.2019 from President and Fellows of Harvard College reports no conflict of interest.

S.H.D. receives funding from NIH (5R01HD088393-02) and reports grants to her institution from Takeda, and consulting for Bayer and UCB, all outside the submitted work.

## 6. Study Funding:

5K08AG053380-02, 1R01AG073410 - 01.

## 7. REFERENCES

1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. *Circulation*. 2017;135(10):e146–e603. [PubMed: 28122885]
2. Katan M, Luft A. Global Burden of Stroke. *Semin Neurol*. 2018;38(2):208–211. [PubMed: 29791947]
3. Moura LMVR, Smith JR, Yan Z, et al. Patterns of Anticonvulsant Use and Adverse Drug Events in Older Adults *Pharmacoepidemiology Drug Safety*. 2020:1–9.
4. By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2019 Updated AGS Beers Criteria(R) for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2019;67(4):674–694. [PubMed: 30693946]
5. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. *JAMA Intern Med*. 2014;174(6):890–898. [PubMed: 24733354]
6. Stanley MA, Wilson NL, Novy DM, et al. Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. *JAMA*. 2009;301(14):1460–1467. [PubMed: 19351943]
7. Wang F, Ma Z, Liu M, Wu X. Potentially inappropriate medications at admission and discharge in older adults: A comparison of the Beers 2019 and 2015 criteria. *Int J Clin Pharmacol Ther*. 2020;58(6):299–309. [PubMed: 32301700]
8. Marra EM, Mazer-Amirshahi M, Brooks G, van den Anker J, May L, Pines JM. Benzodiazepine Prescribing in Older Adults in U.S. Ambulatory Clinics and Emergency Departments (2001–10). *J Am Geriatr Soc*. 2015;63(10):2074–2081. [PubMed: 26415836]
9. Xing D, Ma XL, Ma JX, Wang J, Yang Y, Chen Y. Association between use of benzodiazepines and risk of fractures: a meta-analysis. *Osteoporos Int*. 2014;25(1):105–120. [PubMed: 24013517]
10. Palmaro A, Dupouy J, Lapeyre-Mestre M. Benzodiazepines and risk of death: Results from two large cohort studies in France and UK. *Eur Neuropsychopharmacol*. 2015;25(10):1566–1577. [PubMed: 26256008]

11. Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. *Am J Public Health*. 2010;100 Suppl 1:S105–112. [PubMed: 20147682]
12. Ridda I, Lindley R, MacIntyre RC. The challenges of clinical trials in the exclusion zone: the case of the frail elderly. *Australas J Ageing*. 2008;27(2):61–66. [PubMed: 18713194]
13. Cho S, Lau SW, Tandon V, Kumi K, Pfuma E, Abernethy DR. Geriatric drug evaluation: where are we now and where should we be in the future? *Arch Intern Med*. 2011;171(10):937–940. [PubMed: 21606098]
14. Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. *Fundam Clin Pharmacol*. 2007;21(3):217–230. [PubMed: 17521291]
15. Hernan MA. How to estimate the effect of treatment duration on survival outcomes using observational data. *BMJ*. 2018;360:k182. [PubMed: 29419381]
16. Hernan MA. With great data comes great responsibility: publishing comparative effectiveness research in epidemiology. *Epidemiology*. 2011;22(3):290–291. [PubMed: 21464646]
17. Hernán MA, & Robins JM Authors' Response, Part I: Observational Studies Analyzed Like Randomized Experiments: Best of Both Worlds. *Epidemiology*. 2008;19(6):782–792.
18. Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. *American journal of epidemiology*. 2016;183(8):758–764. [PubMed: 26994063]
19. Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. *J Clin Epidemiol*. 2016;79:70–75. [PubMed: 27237061]
20. Petito LC, Garcia-Albeniz X, Logan RW, et al. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database. *JAMA Netw Open*. 2020;3(3):e200452. [PubMed: 32134464]
21. Dahabreh IJ, Haneuse SJA, Robins JM, et al. Study Designs for Extending Causal Inferences From a Randomized Trial to a Target Population. *Am J Epidemiol*. 2021;190(8):1632–1642. [PubMed: 33324969]
22. Huitfeldt A, Kalager M, Robins JM, Hoff G, Hernan MA. Methods to Estimate the Comparative Effectiveness of Clinical Strategies that Administer the Same Intervention at Different Times. *Curr Epidemiol Rep*. 2015;2(3):149–161. [PubMed: 26587368]
23. Zhang Y, Young JG, Thamer M, Hernan MA. Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies. *Health Serv Res*. 2018;53(3):1900–1918. [PubMed: 28560811]
24. Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a Research Patient Data Repository. *AMIA Annu Symp Proc*. 2006:1044.
25. Ormseth CH, Sheth KN, Saver JL, Fonarow GC, Schwamm LH. The American Heart Association's Get With the Guidelines (GWTG)-Stroke development and impact on stroke care. *Stroke Vasc Neurol*. 2017;2(2):94–105. [PubMed: 28959497]
26. Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIH stroke scale score from medical records. *Stroke*. 1999;30(8):1534–1537. [PubMed: 10436096]
27. Runde D Calculated Decisions: NIH stroke scale/score (NIHSS). *Emerg Med Pract*. 2020;22(7):CD6–CD7.
28. Willis AW, Schootman M, Tran R, et al. Neurologist-associated reduction in PD-related hospitalizations and health care expenditures. *Neurology*. 2012;79(17):1774–1780. [PubMed: 23054239]
29. Colin O, Labreuche J, Deguil J, et al. Preadmission use of benzodiazepines and stroke outcomes: the Biostroke prospective cohort study. *BMJ Open*. 2019;9(1):e022720.
30. Porter B, Arthur A, Savva GM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. *BMJ Open*. 2019;9(5):e026171.
31. Betensky RA, Mandel M. Recognizing the problem of delayed entry in time-to-event studies: Better late than never for clinical neuroscientists. *Ann Neurol*. 2015;78(6):839–844. [PubMed: 26452746]

32. Xu KY, Hartz SM, Borodovsky JT, Bierut LJ, Grucza RA. Association Between Benzodiazepine Use With or Without Opioid Use and All-Cause Mortality in the United States, 1999–2015. *JAMA Netw Open*. 2020;3(12):e2028557. [PubMed: 33295972]
33. Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. *American journal of epidemiology*. 2012;175(4):250–262. [PubMed: 22223710]
34. Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. *Epidemiology*. 2008;19(6):766–779. [PubMed: 18854702]
35. Nordahl H Social inequality in chronic disease outcomes. *Dan Med J*. 2014;61(11):B4943. [PubMed: 25370965]
36. Hirji S, McGurk S, Kiehm S, et al. Utility of 90-Day Mortality vs 30-Day Mortality as a Quality Metric for Transcatheter and Surgical Aortic Valve Replacement Outcomes. *JAMA Cardiol*. 2020;5(2):156–165. [PubMed: 31851293]
37. Fonarow GC, Saver JL, Smith EE, et al. Relationship of national institutes of health stroke scale to 30-day mortality in medicare beneficiaries with acute ischemic stroke. *J Am Heart Assoc*. 2012;1(1):42–50. [PubMed: 23130117]
38. Krumholz HM, Normand SL. Public reporting of 30-day mortality for patients hospitalized with acute myocardial infarction and heart failure. *Circulation*. 2008;118(13):1394–1397. [PubMed: 18725492]
39. Hedges LV, Pustejovsky JE, Shadish WR. A standardized mean difference effect size for multiple baseline designs across individuals. *Res Synth Methods*. 2013;4(4):324–341. [PubMed: 26053946]
40. Tian L Inferences on standardized mean difference: the generalized variable approach. *Stat Med* 2007;26(5):945–953. [PubMed: 16708348]
41. Kloecker DE, Davies MJ, Khunti K, Zaccardi F. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. *Ann Intern Med*. 2020;172(8):541–552. [PubMed: 32203984]
42. Lu Y, Tian L. Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials. *Stat Biopharm Res*. 2021;13(2):210–218. [PubMed: 33927801]
43. Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. *Comput Methods Programs Biomed*. 2004;75(1):45–49. [PubMed: 15158046]
44. Robins JM. Marginal Structural Models. *American Statistical Association*. 1998:1–14.
45. Robins JM, Hernán MA Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G DM, Verbeke G, et al., eds., ed. *Longitudinal Data Analysis*. Boca Raton, FL.: Chapman & Hall; 2009:553–599.
46. Niedrig DF, Hoppe L, Machler S, Russmann H, Russmann S. Benzodiazepine Use During Hospitalization: Automated Identification of Potential Medication Errors and Systematic Assessment of Preventable Adverse Events. *PLoS One*. 2016;11(10):e0163224. [PubMed: 27711224]
47. Ashton H Guidelines for the rational use of benzodiazepines. When and what to use. *Drugs*. 1994;48(1):25–40. [PubMed: 7525193]
48. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. *Lancet Neurol*. 2011;10(5):446–456. [PubMed: 21511198]
49. Krumholz A, Shinnar S, French J, Gronseth G, Wiebe S. Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2015;85(17):1526–1527. [PubMed: 26503589]

**HIGHLIGHTS**

- Quantifying the effect of benzodiazepines on mortality is not straightforward
- Immortal time bias threatens the validity of benzodiazepine effect estimates
- A process of cloning, weighting, and censoring is used to avoid immortal time bias
- The observed benzodiazepine-related 30-day mortality was largely due to confounding

**What is new?**

- Quantifying the effect of benzodiazepines on mortality is not straightforward
- Immortal time bias threatens the validity of benzodiazepine effect estimates
- A process of cloning, weighting, and censoring is used to avoid immortal time bias
- The observed benzodiazepine-related 30-day mortality was largely due to confounding

**Transparency Statement:**


The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported, that no important aspects of the study have been omitted, and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript



**Figure 1. Selection of eligible patients with new acute ischemic stroke (AIS) 65 years, 1/2014–12/2020**

Figure 1 describes the sampling process that resulted in a sample of 2,584 subjects, including patients 65 years, at the time of new acute ischemic stroke admission, patients with available data in the electronic health record system, and patients who had not received benzodiazepines in the months prior to admission.





**Figure 2. Crude and standardized survival curves by benzodiazepine initiation strategy during the first 30 days post-stroke admission**

A. Crude - naïve crude comparison of 30-day mortality with misaligned time zero <sup>a</sup>

<sup>a</sup> Red: No initiation of benzodiazepine within seven days post-AIS admission. Blue: initiation of benzodiazepine within seven days post-AIS admission.

B. Survival curve that fixed the immortal person-time without confounders' standardization <sup>a, b</sup>

<sup>b</sup> Shaded area: 95% confidence intervals constructed using bootstrap with 500 replications.

C. Survival curve fixed the immortal person-time with confounders' standardization <sup>b, c</sup>

<sup>c</sup> This survival curve includes weights for treatment initiation.

**Table 1.**

Description of a randomized trial and the corresponding observational study

<b>RANDOMIZED TRIAL SPECIFICATION</b>	<b>EMULATION (OBSERVATIONAL STUDY)</b>
<b>Eligibility criteria</b>	
Admission for Cerebrovascular Accident between 1/2014 and 12/2020 at Massachusetts General Hospital	Same
Age 65	Same
Confirmed Acute Ischemic Stroke (AIS)	Same
Exclude those with Severe AIS, as defined by a NIHSS above 20	Same, and exclude those without NIHSS recorded at hospital admission
No previous history of AIS	No recorded diagnosis of AIS in the last 12 months
No benzodiazepines in the last 3 months	No recorded prescription of benzodiazepines in the last 3 months
<b>Treatment strategies</b>	
Treatment arm: Initiate benzodiazepine within seven days of admission. Control arm: Do not initiate benzodiazepine within seven days of AIS admission.	Same
<b>Treatment assignment</b>	
Open label, randomized treatment assignment	Emulate randomization by balancing baseline confounders using IPTW for treatment initiation.
<b>Outcomes</b>	
Death during first 30-days	Same. Date of death in EHR (i.e., MGH system <sup>a</sup> ) and/or GWTG (Registry data).
<b>Follow-up</b>	
Starts at randomization (at admission) and ends at date of death, or end of the study (i.e., 30 days post AIS admission), whichever occurs first.	Same
<b>Causal contrast</b>	
Intention-to-treat effect	Observational analog of intention-to-treat effect
<b>Statistical analysis</b>	
Intention-to-treat effect analysis of time to death, accounting for losses to follow up.	Same, additionally accounting for baseline confounding. <sup>b</sup>

Key to abbreviations: AIS = Acute ischemic stroke; ICD=International Classification of Diseases; GWTG=Get-With-The-Guidelines Stroke Registry; IPTW=Inverse Probability of Treatment Weights; MGB=Mass General Brigham; IPCW= Inverse Probability of Censoring Weights.

<sup>a</sup>MGB reliably updates death information from national systems.

<sup>b</sup>Observational analog of intention-to-treat analysis may involve using pooled logistic regression with IPTW and IPCW.

**Table 2.**

Characteristics of patients, by benzodiazepine initiator versus non-benzodiazepine initiator (with start of follow-up aligned at admission)

	Benzodiazepine initiator (N = 389)	Benzodiazepine non-initiator (N = 2195)	SMD
<b>Socio-Demographic Characteristics (recorded at admission)</b>			
Age, mean (SD)	77.96 (8.32)	77.85 (8.42)	0.013
Female (%)	223 (57.3)	1038 (47.3)	0.202
Non-White (%)	34 (9.1)	325 (15.7)	0.200
Ethnicity Hispanic or Latino (%)	2 (0.5)	33 (1.6)	0.103
Primary Insurance Medicare or other government (vs private) (%)	314 (80.7)	1783 (81.3)	0.015
<b>Baseline Medication Use (recorded during the 90 days before admission)</b>			
Prescription Count, Mean (SD)	7.86 (28.81)	4.45 (17.78)	0.143
Categories of Medication use (%)			0.179
No prescription recorded <sup>a</sup>	275 (70.7)	1661 (75.7)	
1–4 drugs	38 (9.8)	247 (11.3)	
5–9 drugs	21 (5.4)	89 (4.1)	
>9 drugs	55 (14.1)	198 (9.0)	
<b>Baseline Clinical Characteristics (recorded during 12 months before admission)</b>			
Charlson Comorbidity Score, mean (SD)	1.18 (1.82)	1.09 (1.66)	0.053
<b>Pertinent Comorbid Conditions (%)</b>			
Sleep disturbance, insomnia	714 (3.6)	55 (2.5)	0.064
Anxiety, dissociative, somatoform disorders	24 (6.2)	101 (4.6)	0.070
<b>Baseline Health-Resource Utilization (recorded during 12 months before admission), %</b>			
Hospitalization	85 (21.9)	505 (23.0)	0.028
Emergency Department (ED)	44 (11.3)	227 (10.3)	0.031
Fall-Related Injury (FRI)	42 (10.8)	227 (10.3)	0.015
Seizure-Like Event (SLE)	17 (4.4)	133 (6.1)	0.076
EEG	5 (1.3)	22 (1.0)	0.027
EEG (Long-term)	1 (0.3)	4 (0.2)	0.016
<b>Acute Ischemic Stroke Severity (recorded at admission), %</b>			
NIHSS (mean (SD))	7.06 (6.56)	5.80 (5.66)	0.205
Minor (0–4)	188 (48.3)	1223 (55.7)	
Moderate (5–15)	131 (33.7)	768 (35.0)	
Moderate-to-severe (16–20)	70 (18.0)	204 (9.3)	

This table describes patient characteristics among benzodiazepine initiators and versus non-initiators, after standardization by age, race, NIHSS and prescription count on the day of admission. SD: standard deviation; SMD: standardized mean difference; EEG: electroencephalogram; ED: emergency department; FRI: fall-related injuries; SLE: seizure-like event; NIHSS: national institutes of health stroke severity: Mild (0–4), Moderate (5–15), Moderate-Severe (16–20).

<sup>a</sup>No prescription recorded: the prescription information was a) missing from the MGB structured health system data warehouse, b) the patient was not taking any prescription drug, c) the patient was taking prescription drugs given elsewhere (e.g., over the counter, prescribed and recorded in other healthcare systems), d) other unknown reason.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript